Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Optimizing timeliness of first appointment with medical oncology: A quality improvement initiative at Northwell Health Cancer Institute.

Kit Cancer Cheng, Nagashree Seetharamu, Amy Morris et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23248

e23248 Background: As part of the quality improvement initiative , the Northwell Health Cancer Institute aimed to improve the average time to first appoin...

Understanding and increasing awareness of social determinants of health of patients with cancer treated by the MD Anderson Oncology Program at Lyndon B Johnson Hospital.

Michael LaPelusa, Janine Wong, Hilary Yu-heng Ma et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23237

e23237 Background: Harris Health serves nearly a quarter of Harris County, the third most populous county in the United States. As a safety-net healthcare...

Neoadjuvant PD-1 inhibitor combined with Nab-paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NCT05522985): A randomized, controlled, open label, phase II clinical trial.

Hongling Wang, Xudong Wang, Yanwei Li et al. Jun 01, 2025 pp. 6018-6018 10.1200/jco.2025.43.16_suppl.6018

6018 Background: More than 60% of head and neck squamous cell carcinoma (HNSCC) patients (pts) were locally advanced at diagnosis. Many previous clinical...

Parenting challenges of international medical graduate hematologists-oncologists in the United States.

Vera Kazakova, Shina Bhatia, Ronit Juthani et al. Jun 01, 2025 pp. 9016-9016 10.1200/jco.2025.43.16_suppl.9016

9016 Background: Almost two-thirds of physicians report delaying childbearing due to medical training. Amongst hematologists-oncologists (HOs), up to 75%...

Computational pathology to predict docetaxel benefit for high-risk localized prostate cancer in NRG/RTOG 0521 (NCT00288080).

Sebastian R. Medina, Naoto Tokuyama, Kamal Hammouda et al. Jun 01, 2025 pp. 1557-1557 10.1200/jco.2025.43.16_suppl.1557

1557 Background: The benefit of adding docetaxel (DTX) to standard of care (SOC) for high-risk localized prostate cancer remains debated. The NRG/RTOG 052...

Clinical characteristics and outcomes of multiple myeloma in Asian Indian and Pakistani Americans (AIPA).

Suhail Sapkota, Sai Sushrutha Mudupula Vemula, Niket Shah et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19558

e19558 Background: Multiple myeloma (MM) is a hematologic malignancy associated with significant morbidity and mortality, including complications like ost...

Utilizing cancer community outreach and engagement to explain impact of age, income, residence, knowledge, and survivorship on cancer fatalism in urban and rural/marginalized areas.

Runcie C.W. Chidebe, Krishna Prasad Sapkota, Leigh Leibel et al. Jun 01, 2025 pp. 10538-10538 10.1200/jco.2025.43.16_suppl.10538

10538 Background: Nigeria has the highest cancer burden in sub-Saharan Africa, with 124,815 incidences and 78,899 deaths. Popular fatalistic beliefs such...

Association of initial abemaciclib dosing with duration of medication use in patients with stage II/III breast cancer on endocrine therapy.

Alexis Marie Espinal, Xueting Tao, Kelley M. Kidwell et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12514

e12514 Background: The CDK 4/6 inhibitor abemaciclib is given to decrease risk of distant recurrence of breast cancer. However, its use has been limited b...

Symptom burden, quality of life (QoL), social and behavioral characteristics in young patients (<40 years old) with cancer: A prospective cohort of 7323 patients across 110 sites in France and Belgium.

Kaïssa Ouali, Christophe Massard, Antoine Hollebecque et al. Jun 01, 2025 pp. 1615-1615 10.1200/jco.2025.43.16_suppl.1615

1615 Background: Cancer in individuals under 40 years old is increasingly recognized as a public health concern, characterized by unique etiologies, biolo...

The efficacy of watch and wait strategy or surgery after neoadjuvant immunotherapy for locally advanced colorectal cancer with dMMR/MSI-H guided by ctDNA dynamic monitoring (WINDOW): A single-center, open-label, prospective, phase II study.

Xuan Zhang, Di Cao, Jie Du et al. Jun 01, 2025 pp. 3559-3559 10.1200/jco.2025.43.16_suppl.3559

3559 Background: Circulating tumor DNA (ctDNA) has shown potential in predicting the efficacy of neoadjuvant treatment for colorectal cancer (CRC). Howeve...

Transforming data management in clinical trials: Uncovering CRC pain points through user research.

Leemor Yuravlivker, Cenia Thomas, Bo Young Kim et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e21001

e21001 Background: Clinical trial timelines are significantly influenced by the efficiency of data transfer from sites’ Electronic Health Records (EHRs) t...

Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer (mCRPC).

Capucine Baldini, Armelle Vinceneux, Debbie G.J. Robbrecht et al. Jun 01, 2025 pp. 5017-5017 10.1200/jco.2025.43.16_suppl.5017

5017 Background: Human kallikrein 2 (encoded by the KLK2 gene and hereafter referred to as KLK2) is a novel target expressed on PC...

Exploring the impact of race, ethnicity, and BMI on neoadjuvant hormonal treatment outcomes.

Traci King, Priscila Barreto Coelho, Samantha El Warrak et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12590

e12590 Background: Neoadjuvant hormonal therapy (NHT) is a treatment option for estrogen receptor-positive (ER+) breast cancer (BC) in postmenopausal wome...

A pilot exercise program in breast cancer survivors: Group vs individual training outcomes.

Lindsey Elizabeth Merifield, Matthew Toyama, Ashley Gooman et al. Jun 01, 2025 pp. 12050-12050 10.1200/jco.2025.43.16_suppl.12050

12050 Background: Exercise interventions have consistently led to improved fitness in breast cancer patients. Best practices to ensure longevity of lifest...

Risk of non-breast cancer–related mortality in breast cancer and dependence on disease characteristics, treatment, and survival duration.

Varsha Gupta, Vinit Singh, Naman Sharma et al. Jun 01, 2025 pp. 12041-12041 10.1200/jco.2025.43.16_suppl.12041

12041 Background: Breast Cancer (BC) has seen significant improvement in survival in both early (eBC) and metastatic (mBC) setting. Prolonged survival inc...

ScRNA-seq profiles to identify HES1 associated with ACTH-secreting tumors and the distinct microenvironment between ACTH+/CRH+ and ACTH-/CRH- pheochromocytomas.

Wan Su, Shiwei Chen, Wencong Han et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16604

e16604 Background: Ectopic ACTH and/or CRH-secreting pheochromocytomas are rare catecholamine-secreting tumors originating from adrenal medulla, which cou...

Trial in progress: A phase Ib/II study to evaluate the safety and efficacy of atezolizumab plus bevacizumab as adjuvant therapy following carbon ion radiotherapy in hepatocellular carcinoma (VANGUARD trial).

Keisuke Koroki, Hirokazu Makishima, Sadahisa Ogasawara et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps4222

TPS4222 Background: While hepatic resection remains the standard curative treatment for hepatocellular carcinoma (HCC), many cases are ineligible due to i...

Unveiling the promising potential of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes: A systematic review and meta-analysis.

Shamikha Cheema, Hassan Ijaz, Sai Sushrutha Mudupula Vemula et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18580

e18580 Background: Myelodysplastic syndromes (MDS) are characterized by ineffective blood cell production. Luspatercept (Reblozyl) is a recently approved...

Clinical effectiveness of urine DNA for minimal residual disease (MRD) monitoring of urothelial carcinoma in urine: A multicenter, prospective, observational study.

Xuanjun Guo, Lei He, Kaiwei Yang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps4617

TPS4617 Background: Limited methods and poor compliance are major issues in urothelial carcinoma (UC) surveillance. Non-invasive monitoring of minimal res...

Evaluating efficacy of targeted microwave ablation in patients with prostate cancer: A systematic review and proportional meta-analysis.

Rameez Qasim, Shree Rath, Muhammad Saffi Ullah et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17133

e17133 Background: Prostate cancer (PC) remains one of the most prevalent malignancies affecting men worldwide. Targeted focal therapies have helped ablat...

Project Shirley: Fear of recurrence and risk communication in Australian HR+ HER2– early breast cancer patients.

Sarah Powell, Jenny Gilchrist, Simone Fraser et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13867

e13867 Background: Fear of cancer recurrence (FCR) significantly affects survivors of hormone receptor-positive (HR+), HER2-negative early breast cancer (...

Clinicopathological features of colorectal cancer in adolescents and young adults (AYA) at a tertiary referral centre in Nigeria.

Sharif Adeniyi Folorunso, Israel Adeyemi Owoade, Olalekan Olasehinde et al. Jun 01, 2025 pp. 3629-3629 10.1200/jco.2025.43.16_suppl.3629

3629 Background: Colorectal cancer (CRC) is traditionally considered a disease of older adults; however, its incidence among AYA has been rising globally....

Multimodal AI using host, tumor, and ghost biomarker for predicting immunotherapy efficacy in NSCLC.

Vanja Miscovic, Marta Brambilla, Laura Mazzeo et al. Jun 01, 2025 pp. 8578-8578 10.1200/jco.2025.43.16_suppl.8578

8578 Background: Almost all NSCLC patients (pts) without driver alterations received a first-line based immunotherapy (IO). It is unclear if pts with very...

A phase I trial of binimetinib plus hydroxychloroquine inpatients with previously treated metastatic pancreatic cancer.

S. Daniel Haldar, Fen Saj, So Jung Hong et al. Jun 01, 2025 pp. 4152-4152 10.1200/jco.2025.43.16_suppl.4152

4152 Background: Combined MEK and autophagy inhibition exerts synergistic antitumor activity in preclinical models of RAS-mutant cancers. We hypothesized...

Understanding patient preferences for supplemental methods of communication of new drug approvals in breast cancer survivors.

Sarah K. Premji, Lisa Halverson, Sharon Lin et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13551

e13551 Background: The landscape of cancer care is evolving rapidly. In 2023, there were 83 new FDA oncology approvals, and 145 interventional treatment (...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page